Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.
Also called NCT07920939
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 450 participants
- Registry
-
NCT07920939
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07920939. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2027-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- SHR-3167 Injection
- Intervention (Drug)
- Insulin glargine (IGlar)
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct07920939- Content hash
6fc74d5b1743e78b28b4a8a8c46a47a4f3f8889212191195e7011cf01a6e6db8